Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Petadeferitrin · SP-420

Small molecule · Inhibitor

Phase 2 Most advanced trial
1 Registered trials

What is Petadeferitrin?

Petadeferitrin is an orally bioavailable iron-chelating agent derived from desferrithiocin. It binds free iron, promoting its excretion and reducing iron accumulation and tissue damage in iron overload. It is studied in beta thalassemia major anemia and myelodysplastic syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SP-420
Drug type
Small molecule
Mechanism
Inhibitor
Pathways
iron chelation, iron excretion
Therapy area
Hematology
In trials of
ICLR
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
WBX54NZ436

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05693909 Phase 2 Beta Thalassemia Major Anemia Recruiting ICLR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Beta Thalassemia Major AnemiaMyelodysplastic Syndrome

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.